drugset
Drugs / EBOPIPRANT
last change Nov 2022 re-read 9 days ago

EBOPIPRANT

also known as OBE022

Small molecule

Investigated by
Cytel Inc. · IQVIA Pty Ltd · ObsEva SA · PhinC Development · Scope International AG

Trials 1

today NCT03369262 · Ph 2
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03369262 Jan 2018 → Jul 2020 — ObsEva SA Unknown No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2022-11-22 XOMA (US) LLC XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon xoma.com ↗
2021-07-27 Organon and Co Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor organon.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as EBOPIPRANT ChEMBL registry synonym — accepted as the source's own label CHEMBL3975522 ↗
Known as OBE022 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03369262 ↗
Modality Small molecule — CHEMBL3975522 ↗
Route Oral “OBE022 will be given orally from Day 1 to Day 7.” NCT03369262 ↗